Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
immunomodulatory nanoparticle
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:combines |
biologic drugs
|
| gptkbp:contains |
gptkb:rapamycin
|
| gptkbp:developedBy |
gptkb:Selecta_Biosciences
|
| https://www.w3.org/2000/01/rdf-schema#label |
ImmTOR
|
| gptkbp:indication |
immune tolerance induction
|
| gptkbp:mechanismOfAction |
inhibits immune response to biologic therapies
|
| gptkbp:patent |
gptkb:Selecta_Biosciences
|
| gptkbp:reduces |
anti-drug antibodies
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:status |
investigational drug
|
| gptkbp:target |
antigen presenting cells
|
| gptkbp:usedIn |
gene therapy
enzyme replacement therapy |
| gptkbp:bfsParent |
gptkb:SEL-212
|
| gptkbp:bfsLayer |
6
|